


# Groundbreaking Research on Ceragenins for Combatting Life-Threatening *Acinetobacter baumannii* Infections

*Ceragnins -- Novel Class of Potent Anti-Infectives --- address the AMR crisis*


PARK CITY, UT, UNITED STATES, July 18, 2024 /EINPresswire.com/ -- [N8 Medical](https://www.n8medical.com) Inc. and its drug subsidiaries [Kinnear Pharmaceuticals, LLC](https://www.kinnearpharma.com) and [Kinnear Pharma AUS Pty Ltd](https://www.kinnearpharma.com) are excited to announce the publication of significant research on ceragenins, demonstrating their potential as powerful agents against [Acinetobacter baumannii](https://www.ncbi.nlm.nih.gov/taxonomy/Acinetobacter_baumannii), a critical-priority pathogen. This research, published in the *International Journal of Molecular Sciences*, highlights the groundbreaking capabilities of ceragenins in preventing and eradicating this life-threatening bacterium infection.

## Key Findings:

- **Efficacy Against Biofilms:** The study assessed ceragenins CSA-13, CSA-44, and CSA-131 on 65 clinical isolates of *A. baumannii*, revealing a strong bactericidal effect, even against biofilm-embedded cells.
- **Membrane Breakdown:** AFM analysis showed significant membrane damage in *A. baumannii* cells treated with ceragenins, indicating their ability to disrupt bacterial cell surface structures.
- **Anti-Adhesive Properties:** In A549 lung epithelial cell cultures, CSA-13 inhibited bacterial



## Bactericidal activities of CSAs



## Anti-biofilm activity

adhesion, suggesting a mechanism for preventing bacterial invasion of host cells and attachment to medical devices.

#### Implications for Antimicrobial Strategies:

These findings underscore the potential of ceragenins as a new class of broad-spectrum antimicrobials, capable of addressing the urgent need for effective treatments against multidrug-resistant pathogens. The research provides a solid foundation for developing new antimicrobial and anti-adhesive strategies to combat nosocomial infections caused by *A. baumannii*.

#### Quotations:

Dr. Robert Bucki, Professor of Medical Microbiology at the Medical University of Białystok and a leading researcher on this study, stated, "Ceragenins show great promise as therapeutic agents for treating *Acinetobacter baumannii* infections, especially against carbapenem-resistant strains. By efficiently destroying bacterial membranes and preventing biofilm development, ceragenins could revolutionize how we manage these severe infections."

Carl Genberg, CEO of Kinnear Pharmaceuticals and Kinner Pharma AUS Pty Ltd, added, "The research highlights CSA-131's significance in treating severe infections, providing a potential breakthrough in antimicrobial therapies. This not only underscores the importance of ceragenins but upon issuance of a QID{P designation will also secure their market exclusivity and expedited FDA processes, facilitating faster patient access to these innovative treatments."

#### About Ceragenins:

Ceragenins are synthetic mimics of cationic antimicrobial peptides, designed to replicate the body's innate immune defense mechanisms. Unlike traditional antibiotics, repeated use of ceragenins do not induce mutational resistance and exhibit broad-spectrum activity, making them effective against a variety of pathogens, including gram-positive and gram-negative bacteria, fungi, and lipid-enveloped viruses such as COVID-19.

#### Future Prospects:

N8 Medical and its Kinnear subsidiaries are committed to advancing the development of ceragenins for clinical use, aiming to transform the treatment landscape for infections caused by multidrug-resistant bacteria. The company envisions the widespread adoption of ceragenin-based therapies to significantly reduce the incidence and impact of hospital-acquired infections.

#### Contact:

Carl Genberg, CEO  
Kinnear Pharmaceuticals, LLC and Kinnear Pharma AUS Pty LTD  
carlgenberg@kinnearpharma.com  
(702) 285-5740 (PDT)

For more information, visit [www.n8medical.com](<http://www.n8medical.com>);www

[www.kinnearpharma.com](http://www.kinnearpharma.com)

---

About N8 Medical Inc and Kinnear.:

N8 Medical Inc. and its Kinnear drug subsidiaries are at the forefront of developing innovative solutions to combat antimicrobial resistance. The company's cutting-edge research and development efforts focus on creating advanced antimicrobial agents to address critical healthcare challenges.

About the Research:

The research titled "Investigating the Effectiveness of Ceragenins against *Acinetobacter baumannii* to Develop New Antimicrobial and Anti-Adhesive Strategies" was conducted by a team of scientists from the Medical University of Białystok and Brigham Young University. The study highlights the potential of ceragenins in developing effective antimicrobial strategies against *A. baumannii*.

For the full research article, visit [MDPI](<https://www.mdpi.com/1422-0067/25/13/7036>).

Carl Genberg

N8 Medical, Inc

+1 7022855740

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/728578949>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.